Skip to main content

Find Clinical Trials

Home
Conditions
Refractory Plasma Cell Myeloma

Clinical trial condition

Refractory Plasma Cell Myeloma

Explore clinical trials studying Refractory Plasma Cell Myeloma. Study availability and eligibility vary by location and protocol.

55 public trials 4 recruiting studies

Refine in advanced search Browse all conditions

Refractory Plasma Cell Myeloma trial results

Active, Not Recruiting

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

NCT05514990

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Los Angeles County-USC Medical Center Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center Los Angeles, California, United States

View Trial Details

Active, Not Recruiting

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT03763162

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Active, Not Recruiting

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

NCT05411497

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States

Mayo Clinic in Arizona Scottsdale, Arizona, United States

View Trial Details

Active, Not Recruiting

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

NCT05391750

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States

View Trial Details

Active, Not Recruiting

Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma

NCT04756401

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: Hackensack University Medical Center Hackensack, New Jersey, United States

State University of New York Upstate Medical University Syracuse, New York, United States

UNC Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States

Carolinas Medical Center/Levine Cancer Institute Charlotte, North Carolina, United States

View Trial Details